PFE : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. These Companies Know The Future Before It Happens

    February 13, 2014
    Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
  3. Buybacks Instead of Capital Investment - Ahead of Wall Street

    January 28, 2014
    Hard to make sense of the fact that companies would consider it prudent to invest in their own sharesinstead of their businesses.
  4. Capital Spending vs. Buybacks - Ahead of Wall Street

    December 24, 2013
    If the Durable Goods report is a sign of things to come, then it would be a material improvement in the economic outlook.
  5. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  6. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  7. Fed Stays on Sidlines, For Now - Ahead of Wall Street

    October 29, 2013
    he Fed isn???t expected to make any changes this time, with Taper not expected to start till April 2014.
  8. Q2 Earnings Season Winding Down - Earnings Trends

    August 1, 2013
    Q2 Earnings Season Winding Down - Earnings Trends
  9. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  10. Tentative Markets Ahead of Big Data - Ahead of Wall Street

    July 30, 2013
    Markets are waiting for looking for confirmation of improved
  11. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  12. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  13. Weak Earnings Growth Outside Finance - Earnings Trends

    July 25, 2013
    Weak Earnings Growth Outside Finance - Earnings Trends
  14. Bull of the Day: Medivation (MDVN) - Bull of the Day

    July 25, 2013
    Bull of the Day: Medivation (MDVN) - Bull of the Day
  15. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  16. Mylan Faces Aptalis Challenge - Analyst Blog

    July 15, 2013
    Mylan has been sued by Aptalis Pharma
  17. Stock Market News for July 15, 2013 - Market News

    July 15, 2013
    Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
  18. BMY/Pfizer Seek to Expand Eliquis Label - Analyst Blog

    July 12, 2013
    Bristol-Myers Squibb Company and partner Pfizer announced that their supplemental New Drug Application for Eliquis has been ...
  19. VIVUS Inks Deal on Spedra - Analyst Blog

    July 11, 2013
    VIVUS announced that it has entered into a license and commercialization in addition to a supply agreement for Spedra with ...
  20. Encouraging Data on Portola's PRT4445 - Analyst Blog

    July 9, 2013
    Portola Pharmaceuticals announced positive results from a phase II study evaluating PRT4445.
  21. Mylan Notches Patent Court Fight Win - Analyst Blog

    July 9, 2013
    Mylan received a favorable verdict in a patent infringement case with Sunovion.
  22. Impax Challenges Toviaz Patent - Analyst Blog

    July 5, 2013
    Impax Laboratories announced that it is looking to get its generic version of Toviaz tablets approved in the US.
  23. New Data on Biogen's Alprolix - Analyst Blog

    July 3, 2013
    Alprolix is currently under FDA review with a response expected by year end.
  24. Data on Roche's Herceptin - Analyst Blog

    July 3, 2013
    Roche recently announced that CHMP in Europe has given a positive opinion on a subcutaneous formulation of Herceptin for ...
  25. Positive Data on BMY/ Pfizer's Eliquis - Analyst Blog

    July 3, 2013
    Bristol-Myers and Pfizer presented encouraging data on Eliquis.
  26. Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog

    July 1, 2013
    The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada
  27. Mylan Inks Deal - Analyst Blog

    July 1, 2013
    Mylan Inc. signed a distribution agreement with Zyomyx.
  28. Stock Market News for July 1, 2013 - Market News

    July 1, 2013
    Benchmarks ended a three day gaining streak on Friday as fears of the Federal Reserve scaling back the bond buying program ...
  29. Benzinga Market Primer: Friday, June 28: End of Month Edition

    June 28, 2013
    Futures Rise On Better Japan DataU.S. equity futures rose in early pre-market trade following lots of stronger than expected ...
  30. VIVUS' Spedra Gets EU Approval - Analyst Blog

    June 27, 2013
    VIVUS announced that the European Commission has cleared Spedra
  31. Novartis' Sandoz Progresses with Biosimilars - Analyst Blog

    June 26, 2013
    Novartis announced that its generic arm, Sandoz, has initiated a phase III study for its biosimilar version of Amgen's (AMGN) ...
  32. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  33. Protalix and Brazil Health Ministry Ink Deal - Analyst Blog

    June 25, 2013
    Protalix signed a supply and technology transfer agreement with Fiocruz for Uplyso for the treatment of Gaucher disease.
  34. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  35. Encouraging Data on Novartis Candidate - Analyst Blog

    June 10, 2013
    Novartis (NVS) recently released encouraging data on its pipeline candidate, LDK378, from a phase I study.
  36. Positive Data on Novartis' Afinitor - Analyst Blog

    June 7, 2013
    Novartis recently announced positive results on Afinitor, from a phase III trial, BOLERO-3 (Breast cancer trials of OraL ...
  37. Make Money From Spinoffs

    June 4, 2013
    According to Barrons, 15 spinoffs have taken place in 2013 through the end of May, 50% more than last year. It seems all ...
  38. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  39. Coty Readies IPO

    May 28, 2013
    Fragrance maker Coty filed a registration statement amendment May 28 that sees it raising as much as $1.2 billion from its ...
  40. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  41. Agilent Misses, Guidance Disappoints - Analyst Blog

    February 15, 2013
    Agilent Technologies' A) fiscal first quarter earnings per share of 63 cents missed the Zacks Consensus Estimate by 4 cents, ...
  42. Agilent Unit & Pfizer Collaborate - Analyst Blog

    February 14, 2013
    Dako, an Agilent Technologies A) subsidiary, has entered into an agreement with Pfizer Inc. (PFE) related to the development ...
  43. Data on Biogen Hemophilia Candidates - Analyst Blog

    February 11, 2013
    Biogen Idec (BIIB) and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia candidates, ...
  44. Protalix Exploring Options - Analyst Blog

    February 7, 2013
    Protalix BioTherapeutics, Inc. (PLX) recently confirmed that it has hired Citigroup, Inc. C) to explore strategic options. ...
  45. Favorable Ruling for Pfizer - Analyst Blog

    February 7, 2013
    Pfizer Inc. (PFE) recently received a favorable ruling in its patent infringement case against Actavis, Inc. (ACT) for Rapamune. ...
  46. Zoetis Commences Trading - Analyst Blog

    February 4, 2013
    Zoetis Inc. (ZTS), the former Animal Health business of Pfizer Inc. (PFE), started trading on the New York Stock Exchange ...
  47. Positive Data on Spectrum Candidate - Analyst Blog

    January 29, 2013
    Spectrum Pharmaceuticals (SPPI) recently announced safety findings from the phase II BELIEF study on belinostat. Spectrum ...
  48. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  49. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  50. FDA to Review Sanofi's Lemtrada - Analyst Blog

    January 29, 2013
    Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has accepted the marketing ...
  51. Market News Fails to Disappoint - Analyst Blog

    January 29, 2013
    As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge the Fed's contribution to ...
  52. Ahead of Wall Street - January 29, 2013 - Ahead of Wall Street

    January 29, 2013
    Tuesday, January 29, 2013 As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge ...
  53. Generic Launch at Dr. Reddy's - Analyst Blog

    January 28, 2013
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) Singulair oral ...
  54. CHMP Positive on Pfizer's Bosutinib - Analyst Blog

    January 23, 2013
    Pfizer Inc. (PFE) recently received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal ...
  55. Patent Extension at Spectrum Pharma - Analyst Blog

    January 22, 2013
    The US Patent and Trademark Office (USPTO) recently extended the patent covering Spectrum Pharmaceuticals' (SPPI) Fusilev ...
  56. SNY's Allerject Launched in Canada - Analyst Blog

    January 22, 2013
    Sanofi (SNY) recently announced that its epinephrine injection, Allerject, is available in Canada for the emergency treatment ...
  57. Bristol-Myers Preview: Will it Miss? - Analyst Blog

    January 21, 2013
    Bristol-Myers Squibb Company (BMY) is scheduled to release its fourth-quarter 2012 results before the opening bell on Thursday, ...
  58. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
  59. Should Third Quarter Results From Forest Laboratories Worry Investors?

    January 17, 2013
    Forest Labs' miss doesn't seem like a thesis-changing event.
  60. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  61. Setback for ArQule, Shares Fall - Analyst Blog

    January 14, 2013
    ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib ...
  62. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  63. Catalyst-Filled 2013 for Onyx - Analyst Blog

    January 9, 2013
    Onyx Pharmaceuticals, Inc. (ONXX) recently provided an update on its performance in 2012 and its plans for 2013. Kyprolis ...
  64. US Approval for Eliquis - Analyst Blog

    December 31, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news when the US Food ...
  65. Bayer Submits Regorafenib in Japan - Analyst Blog

    December 28, 2012
    Bayer Yakuhin Ltd., the Japanese subsidiary of Bayer AG (BAYRY), submitted a marketing authorization application for regorafenib ...
  66. Japanese Approval for Eliquis - Analyst Blog

    December 27, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news with the Japanese ...
  67. Glaxo/THRX's COPD Candidate Advances - Analyst Blog

    December 20, 2012
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced that they have submitted a marketing application to ...
  68. Stock Market News for December 20, 2012 - Market News

    December 20, 2012
    Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into the ...
  69. An End to Drug Patent Woes? - Analyst Blog

    December 14, 2012
    The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
  70. Lilly Plans Trial for Solanezumab - Analyst Blog

    December 13, 2012
    Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The company ...
  71. Merck's Alzheimer's Drug Progresses - Analyst Blog

    December 10, 2012
    Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will ...
  72. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  73. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  74. NVS Discusses Data Readout Plans - Analyst Blog

    November 29, 2012
    Swiss pharmaceutical giant Novartis (NVS) recently announced that it intends to present key data from studies in patients ...
  75. Elan Starts Phase II AD Study - Analyst Blog

    November 28, 2012
    Elan Corporation (ELN) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression ...
  76. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  77. Another Generic from Dr. Reddy's - Analyst Blog

    November 23, 2012
    Dr. Reddy's Laboratories (RDY) recently launched its generic version of Pfizer's (PFE) pulmonary arterial hypertension (PAH) ...
  78. BMY/PFE's Eliquis Cleared in the EU - Analyst Blog

    November 21, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news with the European ...
  79. Pfizer's Lyrica Scores in Study - Analyst Blog

    November 21, 2012
    Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). Results ...
  80. Pipeline Progress at Novartis - Analyst Blog

    November 14, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced positive data on its pipeline candidate, QVA149 ...
  81. EU Nod for Novartis' Votubia - Analyst Blog

    November 13, 2012
    The European Commission (EC) recently approved Swiss pharmaceutical giant Novartis' (NVS) Votubia to treat adults suffering ...
  82. Weak Quarter from Auxilium Pharma - Analyst Blog

    November 8, 2012
    Auxilium Pharmaceuticals, Inc. (AUXL) reported a loss of 21 cents per share in the third quarter of 2012, wider than the ...
  83. Bayer Buys Schiff Nutrition International: Winners All Around

    November 7, 2012
    Bayer announced November 2 that it's buying Schiff for $1.2 billion to bulk up its consumer business.
  84. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  85. Stock Market News for November 2, 2012 - Market News

    November 2, 2012
    Benchmarks finished in the green on the first trading day of November banking on positive consumer confidence and private ...
  86. Glaxo Misses on Both Counts - Analyst Blog

    November 1, 2012
    GlaxoSmithKline (GSK) reported third quarter 2012 earnings of 71 cents per American Depository Share (ADS), well below the ...
  87. Economic Data Deluge Today - Analyst Blog

    November 1, 2012
    We have a flood of economic and earnings reports this morning, but the focus will be on the labor market today ahead of the ...
  88. Ahead of Wall Street - Nov. 1, 2012 - Ahead of Wall Street

    November 1, 2012
    Thursday, November 1, 2012 We have a flood of economic and earnings reports this morning, but the focus will be on the ...
  89. Priority FDA Review for Stivarga - Analyst Blog

    October 31, 2012
    Recently, the HealthCare unit of Bayer (BAYRY) announced that its oncology drug Stivarga (regorafenib) will be reviewed on ...
  90. Solid Quarter at Dr. Reddy's - Analyst Blog

    October 31, 2012
    Dr. Reddy's Laboratories (RDY) reported second quarter fiscal 2013 earnings per American Depositary Share (ADS) of 50 cents, ...
  91. Markets Stay Closed, Some Earnings Delays - Analyst Blog

    October 30, 2012
    Markets remain closed for a second day on Tuesday due to Hurricane Sandy, with published accounts putting the preliminary ...
  92. Ahead of Wall Street - October 30, 2012 - Ahead of Wall Street

    October 30, 2012
    Tuesday, October 30, 2012 Markets remain closed for a second day on Tuesday due to Hurricane Sandy, with published accounts ...
  93. Loss at Elan Wider than Expected - Analyst Blog

    October 25, 2012
    Elan Corporation's (ELN) loss of 5 cents per share (excluding special items) for the second quarter of 2012 was wider than ...
  94. Generic Plavix Hurts Bristol-Myers - Analyst Blog

    October 24, 2012
    Bristol-Myers Squibb Company's (BMY) second quarter 2012 earnings (excluding special items) of 48 cents per share fell short ...
  95. NVO Looking to Expand Portfolio - Analyst Blog

    October 17, 2012
    Denmark-based Novo Nordisk (NVO) is seeking regulatory approval for its hemophilia A candidate turoctocog alfa (NN7008). ...
  96. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  97. Stock Market News for October 17, 2012 - Market News

    October 17, 2012
    Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks into the ...
  98. Abbott Reports Encouraging HCV Data - Analyst Blog

    October 16, 2012
    Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ...
  99. Stock Market News for October 16, 2012 - Market News

    October 16, 2012
    Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks ...
  100. Lilly Up on Alzheimer's Data - Analyst Blog

    October 9, 2012
    Shares of Eli Lilly and Company (LLY) reached a 52-week high of $50.94 on Monday with the company reporting full results ...
  101. How to Invest If Romney Wins the Election

    October 3, 2012
    Though President Barack Obama leads the latest polls, it's too soon to write Mitt Romney off as a winning candidate. And ...
  102. Bayer's Stivarga Gains Approval - Analyst Blog

    September 28, 2012
    The HealthCare unit of Bayer (BAYRY) recently announced that the US Food and Drug Administration (FDA) has cleared its oncology ...
  103. New Target Date for BMY/PFE's Eliquis - Analyst Blog

    September 27, 2012
    The US approval process of Bristol-Myers Squibb Company/Pfizer Inc.'s (BMY/PFE) anti-clotting drug Eliquis (apixaban) is ...
  104. 3 ETFs In Focus As Election Nears

    September 27, 2012
    ETFs have earned the respect of countless investors as viable financial instruments well suited as core building blocs for ...
  105. Glaxo Back on a Neutral Path - Analyst Blog

    September 25, 2012
    GlaxoSmithKline plc (GSK) performed disappointingly in the second quarter of 2012, missing the Zacks Consensus Estimate both ...
  106. CHMP in Favor of Lilly's Cialis - Analyst Blog

    September 25, 2012
    Eli Lilly and Company's (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products ...
  107. CHMP in Favor of BMY/PFE's Eliquis - Analyst Blog

    September 24, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner, Pfizer Inc. (PFE) received some encouraging news with the European ...
  108. CHMP Positive on Novartis' Votubia - Analyst Blog

    September 24, 2012
    Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced that the Committee for Medicinal Products ...
  109. Dr. Reddy's Launches Generic Amoxil - Analyst Blog

    September 21, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of GlaxoSmithKline's (GSK) Amoxil (amoxicillin) ...
  110. CPIX Reports Encouraging Data - Analyst Blog

    September 20, 2012
    Cumberland Pharmaceuticals Inc. (CPIX) recently announced encouraging top-line results from a phase IV study on Caldolor ...
  111. Pfizer-Hisun JV Launched - Analyst Blog

    September 18, 2012
    Pfizer (PFE) and Chinese pharmaceutical company, Zhejiang Hisun Pharmaceuticals, recently announced the launch of their joint ...
  112. New Data on Merck's Insomnia Drug - Analyst Blog

    September 17, 2012
    Merck & Co. (MRK) recently presented new data on its insomnia candidate, suvorexant, at the 21st Congress of the European ...
  113. Perrigo Eyes Pet Care Market - Analyst Blog

    September 17, 2012
    In a bid to diversify its business into the pet care space, Perrigo Company (PRGO) inked a deal to buy substantially the ...
  114. AstraZeneca in Neutral Lane - Analyst Blog

    September 14, 2012
    We are maintaining our Neutral recommendation on AstraZeneca (AZN) with a target price of $49.00. The stock carries a Zacks ...
  115. Abbott-Astellas Collaborate - Analyst Blog

    September 13, 2012
    Abbott Laboratories (ABT) recently announced that it is collaborating with Astellas Pharma Global Development for a phase ...
  116. Sanofi MS Drug Gets Approval - Analyst Blog

    September 13, 2012
    Sanofi (SNY) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis ...
  117. Dr. Reddy's Launches Generic Toprol - Analyst Blog

    September 12, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
  118. Pipeline Progress at CELG, Shares Up - Analyst Blog

    September 7, 2012
    Recently, Celgene Corporation (CELG) announced encouraging data from two phase III studies (PALACE-2, PALACE-3), which evaluated ...
  119. Pfizer's Orphan Drug Approved - Analyst Blog

    September 6, 2012
    Pfizer Inc. (PFE) received approval for another oncology candidate recently. Bosulif (bosutinib) gained US Food and Drug ...
  120. EC Approves Pfizer's Inlyta - Analyst Blog

    September 5, 2012
    Pfizer Inc. (PFE) recently announced European Commission (EC) approval of its renal cell cancer drug, Inlyta (axitinib). ...
  121. Bayer Seeks Regorafenib Approval - Analyst Blog

    September 5, 2012
    The HealthCare unit of Bayer (BAYRY) recently submitted a new drug application (NDA) with the US Food and Drug Administration ...
  122. AstraZeneca's Zinforo Gets EC Nod - Analyst Blog

    August 30, 2012
    AstraZeneca (AZN) recently announced that the European Commission (EC) has approved Zinforo (ceftaroline fosamil) for treating ...
  123. AstraZeneca Recruits New CEO - Analyst Blog

    August 29, 2012
    AstraZeneca (AZN) recently announced that Pascal Soriot has been recruited as the new Chief Executive Officer (CEO) of the ...
  124. Lilly's Alzheimer's Candidate Fails - Analyst Blog

    August 28, 2012
    Eli Lilly and Company (LLY) recently announced much awaited top-line results on Alzheimer's disease candidate, solanezumab ...
  125. Sanofi's Lemtrada US Filing Update - Analyst Blog

    August 28, 2012
    Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has issued a refuse-to-file ...
  126. Bad News for Bristol-Myers - Analyst Blog

    August 27, 2012
    Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback when it announced the discontinuation of the development ...
  127. Sanofi's Auvi-Q Gets FDA Nod - Analyst Blog

    August 17, 2012
    Sanofi (SNY) recently gained US Food and Drug Administration approval for Auvi-Q (epinephrine injection) for the emergency ...
  128. Watson Pharma Sues FDA - Analyst Blog

    August 17, 2012
    Watson Pharmaceuticals Inc. (WPI) recently announced the filing of a lawsuit against the US Food and Drug Administration ...
  129. MWI Vet-IDEXX Bond 'Non-Exclusive' (revised) - Analyst Blog

    August 13, 2012
    MWI Veterinary Supply, Inc. (MWIV), a worldwide distributor of animal health products to veterinarians, has formed a revised ...
  130. MWI Vet-IDEXX Bond 'Non-Exclusive' - Analyst Blog

    August 10, 2012
    MWI Veterinary Supply, Inc., (MWIV), a worldwide distributor of animal health products to veterinarians, has formed a revised ...
  131. Loss at Vivus Wider-Than-Expected - Analyst Blog

    August 10, 2012
    Vivus Inc.'s (VVUS) second quarter 2012 loss of 24 cents per share was wider than the Zacks Consensus loss Estimate of 23 ...
  132. Dr. Reddy's Expands Portfolio - Analyst Blog

    August 9, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) blockbuster asthma ...
  133. Pfizer & JNJ End Bapineuzumab IV - Analyst Blog

    August 7, 2012
    Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is ...
  134. Company News for August 1, 2012 - Corporate Summary

    August 1, 2012
    "    BP plc (ADR) (NYSE:BP) posted second quarter earnings per share of $1.16, missing the Zacks Consensus Estimate of $1.46 ...
  135. Huntington Launches Sector Rotation ETF (HUSE)

    July 30, 2012
    Huntington, fresh off its initial foray into the ETF industry in June, has doubled the size of its lineup with the launch ...
  136. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  137. Amgen Beats, Raises Guidance - Analyst Blog

    July 27, 2012
    Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
  138. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  139. Promising Quarter for Dr. Reddy's - Analyst Blog

    July 23, 2012
    Dr. Reddy's Laboratories (RDY) reported first quarter fiscal 2013 earnings per American Depositary Share (ADS) of 40 cents, ...
  140. Earnings Preview: Bristol-Myers - Analyst Blog

    July 23, 2012
    Biopharmaceutical giant  Bristol-Myers Squibb Company (BMY) is all set to unveil  its second quarter 2012 results before ...
  141. Lyrica Court Win for Pfizer - Analyst Blog

    July 20, 2012
    Pfizer Inc. (PFE) recently received good news with the United States District Court for the District of Delaware upholding ...
  142. Dr. Reddy's Launches Generic Lipitor - Analyst Blog

    July 19, 2012
    Yet another generic version of Pfizer's (PFE) cholesterol drug, Lipitor (atorvastatin calcium), entered the market recently ...
  143. AZN to Restructure Operations - Analyst Blog

    July 18, 2012
    AstraZeneca PLC's (AZN) global biologics division, MedImmune, is set to streamline its infectious disease and vaccines research, ...
  144. Good News for Celgene's Pipeline - Analyst Blog

    July 16, 2012
    Celgene Corporation (CELG) recently announced positive top-line results on its candidate apremilast from a phase III study ...
  145. Merck KGaA's Erbitux Disappoints - Analyst Blog

    July 10, 2012
    Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
  146. What Patent Cliff? Pharma ETFs Continue to Surge - ETF News And ...

    July 10, 2012
    For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment's ...
  147. GolinHarris Acquires Virgo Health - Analyst Blog

    July 6, 2012
    GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
  148. 4 Market-Leading Sectors for Q3

    July 3, 2012
    The technical action in these four sectors suggests that investors should look here as the markets enter the second half ...
  149. The Most Overbought Dow Stocks

    July 3, 2012
    Despite large first-quarter gains, two big Dow stocks show strong monthly chart formations and are worthy of new buying. ...
  150. June's Worst Dow Stocks

    June 30, 2012
    As has been duly noted, the Dow Jones Industrial Average was a juggernaut of an index during the month of June, but naysayers ...
  151. Bristol-Myers/Pfizer get CRL - Analyst Blog

    June 28, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner, Pfizer Inc. (PFE), suffered a setback when the US Food and Drug Administration ...
  152. Health Care ETFs in Focus on Obamacare Supreme Court Decision ...

    June 27, 2012
    In what looks to be the biggest Supreme Court decision since Bush v. Gore, the highest court in the land will give its opinion ...
  153. Good News for Endo's Pain Portfolio - Analyst Blog

    June 15, 2012
    Endo Health Solutions (ENDP) recently announced that the transition of the company's Opana ER franchise to the new version, ...
  154. BMY Presents Positive Data - Analyst Blog

    June 6, 2012
    Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated ...
  155. Bayer's Cancer Candidate Encourages - Analyst Blog

    June 6, 2012
    The HealthCare unit of  Bayer (BAYRY) recently announced that its cancer candidate regorafenib fared well in a phase III ...
  156. Dow 30 Stocks With High Dividends

    June 1, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  157. Treat Stocks Like Savings

    May 15, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  158. Wide Moat Research Vs. S&P 500

    May 11, 2012
    Comparing the performance of the Wide Moat strategy versus the S&P 500.
  159. Merck Biding Its Time

    May 4, 2012
    Merck investors are getting paid to wait until top-line trends improve.
  160. Company News for May 02, 2012 - Corporate Summary

    May 2, 2012
    Company News for May 02, 2012 - Corporate Summary
  161. The 10 Most Overbought Dow Stocks

    May 1, 2012
    Their surprising 2011 outperformance has left many big Dow stocks close to overbought conditions, but several strong performers ...
  162. Don't Underestimate Dividends In A Recession

    April 30, 2012
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  163. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America ...
  164. Nestle Almost Never On Sale

    April 24, 2012
    Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
  165. J&J Sticking Together

    April 23, 2012
    There is turnaround potential at J&J as it regains its former glory. The company has decided that operating a diversified ...
  166. 5 Dow 30 Stocks With Huge Dividends

    March 21, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  167. Treat Stocks Like Savings

    March 20, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  168. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  169. Navellier's Top Dividend Picks

    March 2, 2012
    Louis Navellier reviews the top dividend-paying stocks in his portfolio, which has an overall yield of over 4%. Louis, ...
  170. Profit-Taking Time for This Drug Stock

    February 29, 2012
    Use this opportunity to step out of this stock while it's in rally mode, and if you want exposure in the sector, put your ...
  171. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  172. Costs Keep The Squeeze On Heinz

    February 22, 2012
    Heinz is having difficulties absorbing cost inflation.
  173. Value At Abbott Labs Balances A Lot Of Growth Optimism

    February 14, 2012
    Growth expectations may be too high for Abbott.
  174. Treat Stocks Like Savings

    January 30, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  175. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  176. The Hot ETF for 2012

    January 11, 2012
    Here's a look at the method behind the picking my annual Hot Hand, so even if the pick misfires, at least you can buy into ...
  177. Don't Count Out Healthcare Stocks

    January 6, 2012
    The healthcare sector remains bogged down in a mire of regulation and dwindling spending.
  178. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  179. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure.
  180. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  181. How to Evaluate Global Dividend Stocks

    December 22, 2011
    Dividend yield is the most important factor to use when evaluating investment opportunities, says London-based portfolio ...
  182. 5 Dow 30 Stocks With Huge Dividends

    December 22, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  183. Treat Stocks Like Savings

    December 19, 2011
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  184. 2011's Highest Performing DJIA stocks

    December 15, 2011
    Check out 2011's highest-performing DJIA stocks.
  185. 5 Dow 30 Stocks With Huge Dividends

    November 24, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  186. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  187. Big Values In Big Pharma

    November 1, 2011
    The major pharmaceutical firms now represent value. These companies could represent a great income play.
  188. Merck's Penance Has Gone On Long Enough

    October 31, 2011
    Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
  189. Abbott Has Benefited From Its Diversification

    October 25, 2011
    Why is Abbott deciding to break apart?
  190. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  191. High Yielding Equities

    October 21, 2011
    Despite the market volatility, there are still some stocks and ETFs that pay above-average dividend yields.
  192. What Is Walgreen's Next Trick?

    September 30, 2011
    Walgreen is doing okay today, but tomorrow is a much bigger question.
  193. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  194. 5 Dow 30 Stocks With Huge Dividends

    September 28, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  195. Vivus Tries A New Path

    September 21, 2011
    Vivus takes a more pragmatic approach to getting Qnexa to market.
  196. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
  197. PerkinElmer Adds High-End Tools To Its Box

    September 13, 2011
    Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
  198. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  199. AAA-Rated Stocks Lead S&P 500

    August 25, 2011
    These four blue chips are the only S&P 500 companies with AAA credit ratings, a distinction that shows superior financial ...
  200. Seattle Genetics – And Now The Hard Bit

    August 23, 2011
    Seattle Genetics got a much-needed FDA approval, but the sales ramp could be challenging for the stock.
  201. A Blue-Chip Bargain Hunter's Bonanza

    August 21, 2011
    Valuations for the large caps are reaching the most attractive levels in decades, writes Paul Larson of Morningstar StockInvestor. ...
  202. Why Insiders Are Buying This Biotech Stock

    August 15, 2011
    There are a number of fundamental developments that have spurred recent purchases of Celgene.
  203. Illumina Gets Capped And Cut

    August 4, 2011
    Illumina's sky-high valuation takes a beating on lower guidance.
  204. 3 ETFs to Watch on Debt Deadline Day

    August 4, 2011
    As markets react to the US debt deal, new corporate earnings reports, and lingering Eurozone debt issues, these three ETFs, ...
  205. July's Dow 30 Winners and Losers

    August 3, 2011
    See the best and worst performing DJIA stocks from July 2011!
  206. Don't Underestimate Dividends In A Recession

    July 29, 2011
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  207. 10 Drug Firms to Profit on Biosimilars

    July 28, 2011
    Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
  208. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  209. Drugs Don't Cure All That Ails J&J

    July 20, 2011
    JNJ's performance is mediocre, as are its investment prospects.
  210. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  211. Huge Dividends You Can Bank On

    July 13, 2011
    Stability and longevity of a dividend are good indicators that the company is focused on returning cash to shareholders.
  212. Getting Drugged On Growth

    July 6, 2011
    Valuations look decent for many prescription drug companies.
  213. 4 Dow 30 Stocks With Huge Dividends

    July 6, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  214. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  215. Pleasure And Pain For Pfizer

    June 27, 2011
    Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
  216. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  217. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  218. ETFs To Own And To Avoid

    June 13, 2011
    Investors looking for safety and protection will want to consider the pros and cons of these exchange-traded funds.
  219. 5 Stocks At 52-Week Highs

    June 9, 2011
    Five stocks in five different industries at different points in their business cycle. These stocks are hitting highs in their ...
  220. May's Dow 30 Winners and Losers

    June 1, 2011
    See the best and worst performing DJIA stocks from May 2011!
  221. Treat Stocks Like Savings

    May 30, 2011
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during
  222. With Mylan, Maybe Smaller Is Better

    May 6, 2011
    Mylan is not the biggest or the best, but the valuation here makes it worth a look.
  223. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  224. 7 Dividend Stocks With Big Payouts

    May 4, 2011
    Dividend increases are being seen across the board. Find out which stocks are offering the biggest payouts.
  225. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  226. Lilly Will Pay Investors For Patience

    April 20, 2011
    Lilly isn't dynamic, but the value is there.
  227. Stocks OK Despite Debt Downgrade

    April 20, 2011
    Though there was some panic at the start of the week, the stock market may not be in turmoil just yet.
  228. Amarin's Magic Pill

    April 19, 2011
    Strong clinical data sends Amarin's stock soaring.
  229. Approval In Hand, Does Xenoport Have The Legs To Run?

    April 11, 2011
    Xenoport's pipeline is thin, but Horizant approval buys valuable time.
  230. Merger Monday Recap

    April 5, 2011
    Restaurants, defense, drugs, mining and more made Monday an active day on the M&A front.
  231. Valeant Offers A Princely Sum For Cephalon

    March 31, 2011
    Valeant offers a rare win-win bid for Cephalon.
  232. Treat Stocks Like Savings

    March 17, 2011
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  233. Don't Feel Blue About Blue Chips

    March 10, 2011
    Today's market valuation has diminished the pool of cheap small caps. Boring large caps, on the other hand, seem more attractive ...
  234. Glaxo And Human Genome Find Rare FDA Success

    March 10, 2011
    With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
  235. PBMs: Making The Most Of Generics

    February 3, 2011
    PBMs stand to benefit from the generic introduction of blockbuster drugs. Has the market fully discounted the opportunity?
  236. Abbott's Next Act

    January 27, 2011
    Abbott has significant challenges ahead, but Wall Street seems to assume that the company will lose.
  237. Forest Labs Has Wood To Chop

    January 19, 2011
    Will Forest be able to plug a gaping hole in its future revenue?
  238. A Look At The Drug Makers Of 2010

    December 30, 2010
    Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
  239. Roche Noise May Be A Buyer's Best Friend

    December 22, 2010
    A spate of bad news may have Roche in great value shape.
  240. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  241. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  242. Can New Leadership Rejuvenate Big Pharma?

    December 8, 2010
    Will another new drug company CEO make a difference in a stagnating industry?
  243. November’s Best And Worst Performing Dow 30 Components

    December 1, 2010
    The performance of these Dow 30 stocks was far off market averages.
  244. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact does it ...
  245. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  246. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  247. BIG Dividends, BIG Returns

    October 22, 2010
    High dividend paying stocks are present in many industries. But do you know how to analyze a balance sheet to ensure that ...
  248. Abbott Labs Showing Meaningful Growth

    October 21, 2010
    Abbott might just be the best healthcare stock today.
  249. 5 Dow 30 Stocks With Huge Dividends

    October 1, 2010
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  250. Neogen Is No Bad Egg

    September 28, 2010
    Food safety scares bring new attention to a proven performer.
  251. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  252. Stryker Needs A Growth Resurfacing

    July 22, 2010
    Stryker is a former growth darling struggling to regain its mojo, but the valuation is enticing.
  253. Investing Like A Contrarian

    July 21, 2010
    When everyone is selling, it may be the time to buy, so says contrarian investing.
  254. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  255. Cancer Vaccines Continue To Show Promise

    July 7, 2010
    Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
  256. What Ails Amgen?

    June 30, 2010
    Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
  257. Investing In The Adspend Portfolio

    June 28, 2010
    Does advertising spending predict stock returns? Find out here.
  258. 3 Large Caps To Watch

    June 25, 2010
    A low P/E is not the only reason to consider these large, high-quality businesses.
  259. Pharmaceuticals With Big Returns

    June 22, 2010
    These intriguing Pharmaceuticals currently have big returns.
  260. Stocks That Protect Against Deflation

    June 21, 2010
    Although recent data suggests prices may be falling, inflation may still take over in the long term due to the excess liquidity ...
  261. Big Pharma's On Sale

    June 4, 2010
    Stocks of some of the large pharmaceutical companies are now available at attractive prices.
  262. A Big Deal For Biotechs - ASCO

    May 26, 2010
    ASCO is a major event for the pharmaceutical and biotech industry, and these stocks could shine in the limelight.
  263. Will Adaptive Design Change The BioPharma World?

    May 13, 2010
    Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
  264. Drug Companies With Tasty Medicine

    May 7, 2010
    Merck is just one of the drug companies offering up tantalizing earnings per share.
  265. Relief With Bristol-Myers Squibb

    May 6, 2010
    BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
  266. Pfizer Delivers A Healthy Quarter

    May 6, 2010
    Despite forecasting adjusted earnings of over $2 a share for 2010, Pfizer shares remain at $17.
  267. GlaxoSmithKline On Simmer

    April 30, 2010
    Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
  268. Forest Labs Is Green With Cash

    April 16, 2010
    Look beyond the trees and at the entire Forest, and what you see is a great risk reward opportunity.
  269. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  270. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  271. 5 Reasons To Love Greenlight Capital Re

    March 11, 2010
    David Einhorn, noted investor, is Chairman and largest shareholder of this Cayman Island reinsurance company.
  272. Dow Jones Industrials Play The Share Buyback Game

    March 10, 2010
    A look at five companies from the Dow Jones Industrial Average that repurchased stock in 2007 and how they've done since.
  273. 4 U.S. Companies With High Currency Exposure

    February 24, 2010
    The U.S. dollar has been strengthening against the euro which is a bad sign for the U.S. exporters as the goods become more ...
  274. Drug Stocks That Deserve A Closer Look

    February 19, 2010
    Pharmaceutical stocks have a bright future, and one of my top choices in the space is Merck, which recently released quarterly ...
  275. Several Giants Set To Report

    February 1, 2010
    These big companies have yet to report earnings - and it will be worth it to hear.
  276. Let's Play The Dow Dividend Game

    January 29, 2010
    These three companies are strong alternatives to Dow dividend payers.
  277. There's Nothing Generic About the Profits

    January 27, 2010
    Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will help you ...
  278. Forest Labs' Oh-So-Healthy Balance Sheet

    January 26, 2010
    This company has a pristine capital structure and a stockpile of cash, but the best part is that its stock is cheap.
  279. Excellent Dividend Prospects In 2010

    January 7, 2010
    Today's best businesses are historically high dividend yields, and they shouldn't be ignored in 2010.
  280. Playing Copenhagen With Our Climate Leaders

    January 4, 2010
    With the outcome of the climate meeting uncertain, bet on companies that are already taking steps to reduce their emissions.
  281. 2009's "Dogs of the Dow"

    December 31, 2009
    Was there any bite to the Dogs of the Dow strategy last year?
  282. A Look Back On Deals In 2009

    December 24, 2009
    2009 was an exciting year for mergers, buyouts, industry consolidation plays and hostile takeover attempts.
  283. Why Today's Market Dictates Pessimism

    November 18, 2009
    Investing as if the markets can only go up is a recipe for disaster, while embracing pessimism will keep you in the game.
  284. Treat Stocks Like Savings

    October 28, 2009
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  285. Bears Are Still Growling On Wall Street

    September 1, 2009
    Not every investor is optimistic about the economy, and this attitude shows in an examination of the latest data on short ...
  286. A Quiet Quarter For Berkowitz's Fairholme

    August 19, 2009
    During the second quarter of 2009, Fairholme’s quarterly 13F filing showed a relatively quiet quarter for Fairholme.
  287. High Yield Bets For The Conservative Investor

    July 24, 2009
    High dividends and long-term dependability make it worth getting involved with these companies.
  288. 5 Big Stocks: The Rest Of The Earnings Story

    July 24, 2009
    Earnings aren't the only thing worth reviewing. Here we look at highlights from PepsiCo, Pfizer, Boeing, Overstock and others.
  289. Merck Unloved, But Not For Long

    July 23, 2009
    Merck's release was received without fanfare, but this solid company deserves another look.
  290. A Trio Of High Yielders With Strong Cash Positions

    July 21, 2009
    Here are some safe dividends with a 5% dividend or more, a rarity these days for stocks in the S&P 500.
  291. 6 Stocks The Pros Like

    July 17, 2009
    Watching what professional investors and managers buy is a great way to come up with new stock ideas.
  292. Energizer Keeps Going And Going

    May 15, 2009
    Energizer Holdings just bought the Edge shaving cream business from SC Johnson & Sons, further diversifying its product offerings.
  293. Don't Underestimate Dividends In A Recession

    May 15, 2009
    Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
  294. March Mid Cap Losers

    April 7, 2009
    The five worst performing mid cap stocks in March were in a range of industries, and had little in common except missing ...
  295. Biotech Poised to Disappoint

    April 7, 2009
    The recent wave of big pharma acquisitions does not live up to hype.
  296. Abbott Labs A Solid Pharma Stock

    April 3, 2009
    Abbott Labs has continued to perform solidly as a business and looks poised with its product line to keep going strong.
  297. Why A Merck/Schering Combo Makes Sense

    March 12, 2009
    The Merck/Schering marriage might be a winning combination for both the companies and investors.
  298. Medical Devices: Cure For Ailing Portfolios?

    February 27, 2009
    Find out how these medical device makers may resuscitate your ailing portfolio.
  299. Healthcare Sensitivity According To The Dow

    February 25, 2009
    Beta is a good measure for investors to use, but it is not a guarantee.
  300. Bristol-Myers Pays Healthy Dividends

    February 12, 2009
    Bristol-Myers is among five companies with a great forward annual dividend yield.
  301. Five Dividend Divas For January 15

    January 15, 2009
    Dividend-paying stocks can be a boon for investors. Five have a high forward annual dividend yield and may deserve a closer ...
  302. Big Predictions For Big Pharma

    January 2, 2009
    As defensive plays, Big Pharma stocks could beat the economic crunch.
  303. One More Step For MannKind

    December 4, 2008
    This biotech's inhaled insulin seems to work, but will it sell?
  304. Putting The Dow's Fading Pulse In Perspective

    November 21, 2008
    There's a lot of talk about "historic lows" right now. Learn where the Dow's current metrics really stand in history.
  305. Wyeth's Day In Court

    November 6, 2008
    Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
  306. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  307. How Much Vigor In Invitrogen?

    October 27, 2008
    Invitrogen is in the right space, but does management have the right plan?
  308. Missing Forest Labs For The Trees

    October 27, 2008
    Forest Labs is facing a lull in its pipeline, but prior lulls have been good buying opportunities.
  309. Ride The Ups And Downs Of Drug Approval

    October 16, 2008
    The FDA's complex drug approval process provides plenty of volatility for short-term traders to feast upon.
  310. 10 Blue Chips On The Outs

    October 8, 2008
    The market has taken down stocks of all caliber, and these formerly sturdy blue chip stocks are due another look as we wait ...
  311. Coping With Dow 9,000

    October 7, 2008
    A breakout of the most resilient components in a falling Dow.
  312. Making Sense Of Cash And Shorts

    September 29, 2008
    We examine a group of mutual funds that have large cash positions either from short selling or from asset allocation.
  313. Winners Of The Dow Dog Show For September 3

    September 3, 2008
    Let the Dogs of the Dow strategy point you to potential winners. This week's best of breed is DuPont.
  314. Winners Of The Dow Dog Show For August 27

    August 27, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to rise. This ...
  315. Winners Of The Dow Dog Show For August 19

    August 19, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Best ...
  316. Winners Of The Dow Dog Show For August 11

    August 11, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Pfizer ...
  317. Amgen's $30 Billion Riddle - Biotech Or Big Pharma?

    August 7, 2008
    Amgen's valuations seem too low given recent good news and earnings results. We explore what its new benchmark P/E should ...
  318. Actively Managed ETFs

    August 5, 2008
    Actively managed ETFs need more time to run before investors can truly determine if passive management is superior.
  319. Winners Of The Dow Dog Show For July 29

    July 29, 2008
    The Dogs of the Dow strategy lets investors find undervalued blue chips. This week the best of breed is GE.
  320. Five Dividend Darlings For Monday June 23

    June 23, 2008
    You don't have to be a widow or an orphan to appreciate the staying power that dividend-paying stocks add to your portfolio.
  321. Winners Of The Dow Dog Show

    June 20, 2008
    The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. We ...
  322. Genentech's Avastin Disappoints

    April 11, 2008
    Genentech released earnings that drew mixed reaction from the Street, but on closer inspection the quarter is a clear miss. ...
  323. Monsanto's Double-Bottom Doubles The Fun

    April 8, 2008
    Sometimes a technical trend is so prominent it's impossible to ignore. Monsanto's double-bottom chart could point to a new ...
  324. Novartis' Eye-Catching Deal Won't Add Value

    April 8, 2008
    Novartis is spreading itself too thin with yet another acquisition - this time for vision specialist Alcon.
  325. Duke Energy Is High Yield Royalty

    March 4, 2008
    Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a flight ...
  326. Johnson & Johnson A Defensive Role Model (JNJ)

    January 24, 2008
    JNJ recently reported solid earnings. The stock is nearing the right price for defensive investors seeking no-frills profit ...
  327. Leap Of Faith Healing (MEDX, PDLI, AMLN)

    August 8, 2007
    Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
  328. A 20-Year Supply Of Customers (NVS, PFE, AZN)

    June 7, 2007
    A look at three medicine makers who are set to cash in on 450 million aging baby-boomers around the globe
  329. Ultimate Headache Relief (BAY)

    May 17, 2007
    Investors seeking big pharma exposure often confine themselves to the United States, but the best drug company just might ...
  330. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  331. Schering's Big Deal (SGP)

    March 13, 2007
    An inside look at Schering Plough's big deal to buy Organon BioSciences.
  332. You Gotta Know When To Bail

    February 22, 2007
    When your stock's prospects take a turn for the worse, bailing out can be the best possible option.
  333. Diversify Your Pharmaceuticals With The Middleman (PPDI)

    December 12, 2006
    PPDI proves to be an interesting play on the strong pharmaceutical macro-trend at work in the United States.
  334. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  335. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center